Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00480025 · ClinicalTrials.gov registry record · Phase 3
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,278
- Enrollment target
NCT00480025: Clinical Trial Phase 3 study, sponsored by GlaxoSmithKline.
NCT00480025 is a Phase 3 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 2,278 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (195% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00480025, a Phase 3 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,278 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Primary Outcome
DFS = time interval from randomization to 1st evidence of recurrence/death, if occurring before. All recurrence types were included, including local, regional \& distant metastasis \& 2nd primary lung cancer (i.e. local recurrence, defined as a tumor within same lung or at bronchial stump; regional recurrence, involving a clinically or radiologically manifest disease in mediastinum or supraclavicular nodes; \& distant recurrence \[any tumor arising in contralateral lung or outside hemithorax\]).
Interventions
- BIOLOGICAL Placebo Control
- BIOLOGICAL GSK1572932A Antigen-Specific Cancer Immunotherapeutic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,278 participants |
| Start Date | 2007-10-04 |
| Est. Completion | 2014-09-23 |
| Phase | Phase 3 |
Why NCT00480025 stopped before completion
NCT00480025 is an interventional study that assigns participants to a tested intervention. Its 2,278 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (195% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo Control is the first listed.
NCT00480025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00480025 about?
NCT00480025 is a clinical study titled "GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer". The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in ...
What is the current status of trial NCT00480025?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,278 participants. The study started on 2007-10-04. Estimated completion is 2014-09-23.
What interventions are being tested in trial NCT00480025?
The interventions under investigation include: Placebo Control (BIOLOGICAL), GSK1572932A Antigen-Specific Cancer Immunotherapeutic (BIOLOGICAL).
Who is sponsoring clinical trial NCT00480025?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00480025's enrollment target sits among peer trials
2,278 94th of 2000 higher than 1,907 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03968393 · 2,270 participants · Phase 4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
- NCT05530343 · 2,298 participants · NA
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
- NCT05237258 · 2,300 participants · NA
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI